55.7 F
San Diego
Tuesday, Mar 19, 2024
-Advertisement-

VentiRx Raises $25M

San Diego-based VentiRx Pharmaceuticals said Jan. 12 that it has raised $25 million in an extended round of Series A financing, bringing its total raised to $51.8 million.

MedImmune Ventures, the investment arm of AstraZeneca’s MedImmune, led the round. Existing investors ARCH Venture Partners, Domain Associates and Frazier Healthcare Ventures also participated.

VentiRx is developing a portfolio of drugs in the areas of cancer and respiratory and inflammatory diseases. The company said it plans to use the latest round of funding to support midstage trials of its toll-like receptor 8 drug candidates VTX-2337 for cancer and VTX-1463 for allergic rhinitis.

— Heather Chambers

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-